Methadone vs Suboxone: How the Two Most-Used MAT Medications Compare

What is methadone?

Methadone is a synthetic full mu-opioid receptor agonist used in medication-assisted treatment for opioid use disorder. It was first synthesized in Germany in the 1930s, approved by the FDA for opioid use disorder treatment in 1972, and is the longest-studied medication in the OUD treatment arsenal. Methadone for OUD is dispensed in oral liquid (most common) or tablet form, typically once daily.

Pharmacologically, methadone binds the mu-opioid receptor as a full agonist with high affinity. Its half-life is long — typically 15 to 60 hours — which produces stable receptor occupancy and effective suppression of withdrawal and cravings on once-daily dosing. Unlike buprenorphine, methadone has no ceiling effect on its mu-receptor activity; doses can be titrated upward as needed (within clinical reason) to suppress withdrawal in patients with very high tolerance.

In the United States, methadone for opioid use disorder is dispensed only at SAMHSA-certified opioid treatment programs (OTPs) under 42 CFR Part 8. The regulatory framework requires:

• Daily on-site dosing in early treatment, with graduated take-home privileges based on documented stability (up to 28 days take-home for stable patients per the SAMHSA 2024 final rule)
• Federally mandated counseling integration
• Drug screening at federally specified intervals
• Initial and ongoing assessment by qualified clinical staff

SAMHSA estimates approximately 400,000 to 500,000 patients are receiving methadone for opioid use disorder in the United States in 2026, dispensed across roughly 2,000 OTPs nationwide. Methadone is also used in clinical settings as an analgesic for chronic pain (a different prescribing pathway), but pain prescribing is outside the scope of this guide.

What is Suboxone?

Suboxone is a brand-name combination medication containing buprenorphine (a partial mu-opioid receptor agonist) and naloxone (an opioid antagonist). Generic buprenorphine/naloxone is widely available and clinically equivalent. Suboxone is approved by the FDA for the treatment of opioid use disorder and is dispensed as a sublingual film or tablet that the patient self-administers, typically once daily.

Pharmacologically, buprenorphine binds the mu-opioid receptor as a partial agonist with very high affinity and slow dissociation. Two clinical features follow from the partial-agonist mechanism: a ceiling effect on respiratory depression that makes overdose deaths from buprenorphine alone exceptionally rare, and a milder subjective opioid experience that helps stabilize patients without producing the euphoria of full agonists. The naloxone component is included as an abuse-deterrent: when Suboxone is taken sublingually as directed, naloxone is poorly absorbed and inactive; when injected or misused intranasally, naloxone precipitates withdrawal in opioid-dependent patients, which discourages diversion.

Buprenorphine for opioid use disorder is prescribed in office settings under standard DEA registration. Before January 2023, prescribers needed an X-waiver (a special DEA registration with patient caps); the MAT Act 2023 eliminated the X-waiver, allowing any DEA-registered practitioner to prescribe buprenorphine. The DEA's 2025 permanent rule on buprenorphine telehealth makes audio-video prescribing without prior in-person evaluation permanent law.

SAMHSA estimates approximately 1.5 to 2 million patients are prescribed buprenorphine for opioid use disorder in the United States in 2026. In addition to the daily film or tablet, buprenorphine is also available as long-acting injections: Sublocade (once monthly) and Brixadi (weekly, bi-weekly, or monthly depending on dose).

Side-by-side: methadone vs Suboxone

The table below summarizes how methadone and Suboxone differ across the variables that most affect patient experience and clinical fit. Source data: FDA labels via DailyMed, the ASAM National Practice Guideline, and SAMHSA TIP 63.

Efficacy and outcomes

The most important clinical question patients ask is whether one medication produces better outcomes than the other. The short answer: at adequate doses, both medications produce comparable outcomes; at low buprenorphine doses, methadone retains more patients in treatment.

The most rigorous direct comparison comes from the Cochrane review by Mattick et al. (2014), which pooled data from 31 randomized controlled trials with 5,430 participants. Key findings:

• Treatment retention: at flexible doses (≥8 mg buprenorphine and ≥60 mg methadone), retention rates were comparable between the two medications. At low buprenorphine doses (≤6 mg), methadone retained substantially more patients.
• Illicit opioid use: both medications produced large reductions in illicit opioid use compared to placebo and detoxification-only approaches.
• Cocaine use during treatment: no significant difference between buprenorphine and methadone.
• Adverse events leading to discontinuation: similar rates between the two medications.

The Sordo et al. (BMJ 2017) meta-analysis pooled data from 19 cohort studies covering 122,885 patients and 1.3 to 13.9 years of follow-up. Both methadone and buprenorphine reduced all-cause mortality by approximately 50 to 75 percent compared to no treatment, with overlapping confidence intervals. Mortality reduction is the strongest endpoint in the literature.

The clinical takeaway: at adequate doses, the choice between methadone and Suboxone is rarely a question of efficacy. It is a question of patient profile, clinical fit, treatment setting, and life circumstances.

Safety profile differences

Both medications have established safety profiles when prescribed and monitored appropriately, but the safety profiles differ in clinically important ways.

Buprenorphine has a ceiling effect on respiratory depression. Above a certain dose (typically around 24 to 32 mg sublingual), additional buprenorphine does not produce additional respiratory depression. This makes overdose deaths from buprenorphine alone exceptionally rare. Combined misuse with respiratory depressants (benzodiazepines, alcohol, other opioids) can still produce dangerous respiratory depression, but the ceiling protects against the dose-response curve that drives full-agonist overdose deaths.

Methadone has no ceiling. Methadone overdose is possible, particularly during induction (when the drug is accumulating in tissues) or in combination with respiratory depressants. OTP induction protocols are designed to manage this risk, but methadone-related overdose deaths do occur and are documented in CDC mortality data.

Methadone has documented QT prolongation risk. At higher doses, methadone can prolong the QT interval on the electrocardiogram, which raises the risk of torsades de pointes (a potentially fatal arrhythmia). Baseline and periodic ECG monitoring is recommended at maintenance doses above approximately 100 to 120 mg per day, particularly in patients with cardiac risk factors. Buprenorphine has minimal QT effect at clinical doses.

Drug interactions. Methadone is metabolized primarily by CYP3A4 and CYP2B6; it has substantial interactions with CYP3A4 inducers (rifampin, phenytoin, carbamazepine) and inhibitors (some antifungals, antiretrovirals). Buprenorphine is also metabolized by CYP3A4 but with fewer clinically significant interactions in everyday practice.

Common side effects shared by both: constipation, sweating, sexual dysfunction, sleep disturbance. These tend to lessen over time and are managed with dose adjustments and supportive care.

Who fits Suboxone, who fits methadone?

The right medication depends on patient profile, medication response history, life circumstances, and clinical judgment. The lists below describe typical patient profiles based on SAMHSA TIP 63, the ASAM National Practice Guideline, and current clinical practice.

Patients typically best served by Suboxone

• Most patients with opioid use disorder — including severe OUD, fentanyl exposure, prescription-pill dependence, and kratom or 7-OH dependence
• Work, school, family, or caregiving obligations that make daily on-site clinic visits impractical
• Geographic distance to the nearest OTP — common across rural Tennessee and North Georgia where OTPs concentrate in larger metros
• Preference for medical-office privacy — Suboxone visits look like primary-care appointments
• Buprenorphine-responsive treatment history — per Mattick 2014 Cochrane, retention at adequate doses is comparable to methadone
• Telehealth-friendly: post-2025 DEA rule, follow-up visits can be scheduled remotely
• Patients with cardiac risk factors who would require ongoing ECG monitoring on methadone

Patients typically best served by methadone

• Severe opioid use disorder with very high tolerance who have not responded to thoughtful high-dose buprenorphine, including long-acting injectables and dose optimization — a small subset, not the typical OUD patient
• Multiple thoughtful buprenorphine attempts (including long-acting injectables) without stable response — methadone's full-agonist pharmacology can succeed in the smaller cohort where buprenorphine has not
• Patient preference for methadone specifically — some patients have prior positive experience with methadone or feel it fits their physiology better
• Some Medicaid programs route severe-OUD patients to OTP methadone based on treatment-history criteria

Importantly, the choice is not permanent. Patients can transition from one medication to the other if clinical fit changes — transitioning from methadone to Suboxone is a routine pathway after methadone has stabilized the patient and the lifestyle constraints of daily OTP visits become limiting; transitioning from Suboxone to methadone is also routine if buprenorphine is not adequately suppressing withdrawal or cravings.

Special populations

Pregnancy

Both methadone and buprenorphine are recommended for opioid use disorder during pregnancy by the American College of Obstetricians and Gynecologists and SAMHSA. Methadone has the longer track record and the larger pregnancy safety database. Buprenorphine has a growing evidence base; the MOTHER trial (Jones et al., NEJM 2010) found that infants exposed to buprenorphine in utero required less morphine (89 percent less) and shorter hospital stays for neonatal abstinence syndrome compared to methadone-exposed infants, with similar rates of NAS occurrence. Both medications are considered acceptable; choice involves clinical conversation between the patient, addiction medicine team, and obstetric care.

Fentanyl-using patients

Fentanyl-exposed patients are a large share of who walks through Restoration Recovery's doors, and the vast majority get sober on buprenorphine. Fentanyl's lipophilic profile (it accumulates in body fat) does extend the withdrawal timeline compared to short-acting opioids like heroin — that's a familiar pattern to our clinical team, not an obstacle. We handle fentanyl induction every day. If standard induction needs adjustment, the team has options: longer waiting periods, micro-induction (small buprenorphine doses introduced while still using), or starting with a long-acting injectable like Sublocade or Brixadi that bypasses the daily film/tablet induction entirely. The right answer is the one that works for you.

Adolescents

The American Academy of Pediatrics and ASAM recommend buprenorphine as first-line for adolescents and young adults under 25 unless severity warrants otherwise. Methadone is available in some OTPs for adolescents 16 and older, but federal regulations require parental consent and other additional safeguards.

Patients with chronic pain plus opioid use disorder

Both medications have analgesic activity. Buprenorphine is increasingly used for chronic pain at higher doses (Belbuca, Butrans patches, off-label sublingual), and its ceiling effect makes it a safer chronic-pain option than full-agonist opioids. Methadone is also used for chronic pain through a different prescribing pathway. Patients with co-occurring chronic pain and OUD benefit from coordinated care between addiction medicine and pain management.

How treatment access differs

The biggest practical difference between methadone and Suboxone is the treatment setting required to access them. This is a regulatory distinction governed by federal law and discussed in detail in our companion guide on OBOT vs OTP.

In short: methadone for opioid use disorder is dispensed only at SAMHSA-certified opioid treatment programs (OTPs) under 42 CFR Part 8, which requires daily on-site dosing in early treatment with graduated take-home privileges. Suboxone is prescribed in standard medical offices under DEA registration; the patient picks up the prescription at a pharmacy and takes the medication daily at home. Permanent telehealth flexibility for buprenorphine prescribing is a structural advantage of the Suboxone pathway that methadone does not currently share.

Restoration Recovery and buprenorphine-based MAT

Restoration Recovery prescribes buprenorphine-based MAT across all four clinics — Chattanooga, Cleveland, Soddy-Daisy, and Ringgold. We offer Suboxone (daily film or tablet), Sublocade (once-monthly injection), and Brixadi (weekly, bi-weekly, or monthly injection). For patients with alcohol use disorder, we also prescribe Vivitrol and Acamprosate.

We do not dispense methadone. As an office-based opioid treatment (OBOT) clinic, we are not certified under 42 CFR Part 8 as a SAMHSA opioid treatment program; methadone for opioid use disorder requires that certification. Patients whose clinical situation is best served by methadone can find SAMHSA-certified OTPs through SAMHSA's Find Treatment locator. Both pathways are evidence-based; the right choice depends on the clinical situation, not on a hierarchy of treatment quality.

For patients deciding between Suboxone and methadone, our intake team can walk through the considerations during a 5-minute screening call. If buprenorphine-based treatment is the right fit, we can typically offer a same-week first appointment. If methadone via an OTP is the right fit, we will tell you so directly and point you toward the SAMHSA locator.

Frequently asked questions

Is methadone or Suboxone better for opioid use disorder?

Neither is uniformly better. Both are FDA-approved first-line treatments. Mattick 2014 Cochrane found comparable retention at adequate doses; Sordo 2017 BMJ found both reduce all-cause mortality by approximately 50 to 75 percent. The right medication depends on patient profile, medication response history, life circumstances, and clinical judgment.

Why does Restoration Recovery use Suboxone instead of methadone?

Restoration Recovery operates as an OBOT clinic, not a SAMHSA-certified OTP. Methadone for opioid use disorder can only be dispensed at OTPs under federal law. Our four clinics provide buprenorphine-based MAT (Suboxone, Sublocade, Brixadi), which fits the medication needs of most adults with opioid use disorder. Patients whose situation is best served by methadone can find OTPs through findtreatment.gov.

Can I switch from methadone to Suboxone?

Yes. Transitioning from methadone to Suboxone is a routine clinical pathway. The transition typically requires a methadone taper to a low dose (commonly 30 mg per day or less), then a structured switch to buprenorphine when the patient is in mild withdrawal. Some clinical teams use micro-induction protocols to bridge the transition. Many patients moving from methadone to Suboxone find the once-monthly injection options (Sublocade, Brixadi) particularly attractive after years of daily clinic visits.

Is Suboxone "just as addictive" as methadone?

Both medications produce physical dependence, but neither produces the cycle of compulsive misuse, lost control, and life consequences that defines opioid use disorder when patients are appropriately dosed. Buprenorphine's partial-agonist pharmacology produces a ceiling effect on respiratory depression and a milder subjective experience compared to full agonists. Both medications are tools that treat the underlying disorder; physical dependence on a treatment medication is not the same as the disorder being treated.

I am pregnant. Methadone or Suboxone?

Both are recommended for opioid use disorder during pregnancy by ACOG and SAMHSA. Methadone has the longer track record. Buprenorphine has a growing evidence base; the MOTHER trial found buprenorphine-exposed infants required less morphine (89 percent less) and shorter hospital stays for neonatal abstinence syndrome. Both are considered acceptable; the right choice is a clinical conversation involving addiction medicine and obstetric care.

I have been using fentanyl. Will Suboxone work for me?

Yes. Hundreds of fentanyl-exposed patients have come to Restoration Recovery, started Suboxone, Sublocade, or Brixadi, and stayed in long-term recovery. Fentanyl's longer-than-heroin withdrawal timeline is a familiar pattern to our clinical team — we handle fentanyl induction every day. If standard induction needs adjustment in your case, the team has options: longer waiting periods, micro-induction, or starting on a long-acting injectable that bypasses the daily induction entirely. The right answer is the one that works for you, and our team will help you find it on day one.

Sources and references

1. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2014, Issue 2.
2. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550.
3. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure (MOTHER trial). New England Journal of Medicine 2010;363:2320-2331.
4. American Society of Addiction Medicine. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder — 2020 Focused Update.
5. Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series.
6. Code of Federal Regulations. 42 CFR Part 8: Medication Assisted Treatment for Opioid Use Disorders.
7. U.S. Food and Drug Administration. DailyMed — FDA labels for methadone (Methadose, Dolophine) and buprenorphine/naloxone (Suboxone).
8. Substance Abuse and Mental Health Services Administration. Final Rule: Medications for the Treatment of Opioid Use Disorder. Federal Register, February 2, 2024.
9. Drug Enforcement Administration. Expansion of Buprenorphine Treatment via Telemedicine Encounter. Federal Register, January 17, 2025.
10. 117th Congress. Consolidated Appropriations Act, 2023, Public Law 117-328 — Section 1262 (Mainstreaming Addiction Treatment Act of 2023).
11. Substance Abuse and Mental Health Services Administration. FindTreatment.gov — the federal locator for licensed substance use treatment, including OTPs.